Mesoblast Limited (ASX: MSB) - Share Price

- Current share price for MSB : $2.040

Mesoblast Limited (MSB), an ASX-listed company, is a Company that is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of inflammatory conditions. The therapies from the Company's proprietary mesenchymal lineage cell therapy technology platform respond to inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in reduction of the damaging inflammatory process.

MSB General Information ⁺

ASX Code	MSB
Website	http://www.mesoblast.com
Industry/Sector	Biotechnology
Market Cap ($M)	2,649
MSB Share Price	$2.040
Day High	$2.120
Day Low	$1.995
Last Close	$2.040
MSB Share Price Movement	- ( No change )

Prices as at 16:40, 30 Jul 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Mesoblast Limited (MSB) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Mesoblast Limited (MSB) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Mesoblast Limited (MSB) price-sensitive announcements

MSB - Quarterly Activities/Appendix 4C Cash Flow Report

The Quarterly Activities Report and Appendix 4C Cash Flow Report for Mesoblast Limited (AS

Mesoblast Limited (MSB)
30 Jul 2026 | 10:01 AM

MSB - Pivotal Phase 3 Trial in CLBP Achieves 300 Treated Patients

Mesoblast Limited announced the completion of their target of treating 300 patients in the

Mesoblast Limited (MSB)
14 Jul 2026 | 10:00 AM

MSB - Ryoncil Q4 Net Revenue of US$36M and US$115M for Full Year

Mesoblast Limited announced that their product, Ryoncil® (remestemcel-L-rknd), achieved a

Mesoblast Limited (MSB)
10 Jul 2026 | 9:57 AM

MSB - Mesoblast Draws US$50M from Five-Year Non-Dilutive Facility

Mesoblast Limited has announced the drawdown of US$50 million from a five-year non-dilutiv

Mesoblast Limited (MSB)
25 Jun 2026 | 9:55 AM

Mesoblast Limited (MSB) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Mesoblast Limited (MSB) ORDINARY FULLY PAID	Health Care	$2,649	Quarterly Activities/Appendix 4C Cash Flow Report	30 Jul 2026 10:01AM	$2.010	$2.040	risen by 1.49%
Mesoblast Limited (MSB) ORDINARY FULLY PAID	Health Care	$2,649	Ceasing to be a substantial holder	24 Jul 2026 5:00PM	$2.220	$2.040	fallen by 8.11%
Mesoblast Limited (MSB) ORDINARY FULLY PAID	Health Care	$2,649	Ceasing to be a substantial holder	22 Jul 2026 8:23AM	$2.320	$2.040	fallen by 12.07%
Mesoblast Limited (MSB) ORDINARY FULLY PAID	Health Care	$2,649	Mesoblast CEO Makes Investment to Increase Share Ownership	21 Jul 2026 9:53AM	$2.430	$2.040	fallen by 16.05%
Mesoblast Limited (MSB) ORDINARY FULLY PAID	Health Care	$2,649	Appendix 3Y - Silviu Itescu	21 Jul 2026 9:47AM	$2.430	$2.040	fallen by 16.05%
Mesoblast Limited (MSB) ORDINARY FULLY PAID	Health Care	$2,649	Notification regarding unquoted securities - MSB	21 Jul 2026 9:43AM	$2.430	$2.040	fallen by 16.05%

MSB Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2027F	C2	-$0.90	-85.90%	0.00%	0.0%
2026F	C2	-$6.10	-50.50%	0.00%	0.0%
2025A	-$148.88	-$12.30	3.00%	0.00%	0.0%

MSB Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2025 A	2026 F	2027 F	2025 A	2026 F	2027 F	2025 A	2026 F	2027 F
CSL Limited (CSL)	$61,334M	0.1108	-0.1195	0.0168	13.7330	15.5966	15.3396	3.48%	2.85%	2.96%
Clinuvel Pharmaceuticals Limited (CUV)	$484M	0.0287	0.0000	0.0000	13.3565	0.0000	0.0000	0.52%	0.00%	0.00%
Immutep Limited (IMM)	$69M	0.1854	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Mesoblast Limited (MSB)	$2,649M	0.0301	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Telix Pharmaceuticals Limited (TLX)	$4,927M	-1.3893	0.0000	-0.1426	0.0000	237.7049	277.2467	0.00%	0.00%	0.00%

MSB Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.00	0.00	2.86	0.00
Market	0.59	17.40	1.61	1.01
Sector	0.47	34.10	2.36	2.36

MSB Directors

Name	Position	Start Date
Professor Silviu Itescu	Chief Executive Officer, Executive Director	8 Jun 2004
Dr Eric A Rose	Executive Director	15 Apr 2013
Ms Jane Catherine Bell	Non-Executive Director	18 Aug 2022
Dr Philip R Krause	Non-Executive Director	24 Mar 2022
Ms Lynette Elizabeth Cobley	Non-Executive Director	29 Apr 2025
Dr Gregory George	Non-Executive Director	24 Feb 2025
Mr Philip J. Facchina	Non-Executive Director, Non-Executive Chairman	29 Mar 2021
Mr William (Bill) A Burns	Non-Executive Director, Vice-Chairman	6 Mar 2014

Mesoblast Limited (MSB) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
17 Jul 2026	ITESCU, Silviu	Exercise	Options	1,885,334	$1.450	$2,733,734.000
17 Jul 2026	ITESCU, Silviu	Buy	Direct Shares	1,885,334	$1.450	$2,733,734.000
10 Apr 2026	GEORGE, Gregory	Buy	Indirect Shares	7,210,962	$1.445	$10,418,591.090

See all changes in directors' interest & trades for Mesoblast Limited (MSB) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

MSB Management

Name	Position
Eric Rose	Chief Medical Officer
Andrew Chaponnel	Chief Financial Officer
Peter Howard	Group General Counsel and Corporate Executive
Justin Horst	Head of Manufacturing
Geraldine Storton	Head of Regulatory Affairs and Quality Management
Fiona See	Head of Translational Research
Niva Sivakumar	Joint Company Secretary
Paul Hughes	Joint Company Secretary
Michael Schuster	Pharma Partnering
Paul Simmons	Scientific Advisor to the Chief Executive Officer

MSB Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Mesoblast Limited (MSB). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
267,021,132 (20.86%)	Gregory George Patching
78,958,928 (6.16%)	Silviu Itescu
64,171,900 (5.01%)	William Gueck

MSB Calendar of Events

Date	Event
26 February 2027	Report (Interim)
26 October 2026	Report (Annual)
28 August 2026	Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us